(0.23%) 5 143.25 points
(0.17%) 38 508 points
(0.32%) 17 902 points
(-0.35%) $83.56
(1.82%) $1.958
(0.19%) $2 351.70
(0.50%) $27.67
(0.87%) $930.15
(-0.05%) $0.934
(-0.18%) $11.00
(-0.18%) $0.799
(1.28%) $93.05
@ $23.69
発行日: 14 2月 2024 @ 23:41
リターン: 44.58%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 11.15 %
Live Chart Being Loaded With Signals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...
Stats | |
---|---|
本日の出来高 | 90 155.00 |
平均出来高 | 452 214 |
時価総額 | 359.39M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-1.090 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.32 |
ATR14 | $0.107 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Moran Sean F. | Buy | 1 787 | Common Stock |
2024-04-10 | Moran Sean F. | Sell | 1 787 | Employee Stock Option (right to buy) |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 8 862 | Common Stock |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 156 597 | Common Stock |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 61 668 | Common Stock |
INSIDER POWER |
---|
99.57 |
Last 95 transactions |
Buy: 14 080 389 | Sell: 365 661 |
ボリューム 相関
Corbus Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
MSBI | -0.949 |
BWFG | -0.948 |
NFBK | -0.946 |
CNOB | -0.944 |
ONB | -0.944 |
PFBC | -0.944 |
FBIZ | -0.943 |
PGC | -0.943 |
BCBP | -0.941 |
WSFS | -0.941 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Corbus Pharmaceuticals 相関 - 通貨/商品
Corbus Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2023 |
収益: | $0 |
総利益: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.49M (0.00 %) |
EPS: | $-13.39 |
FY | 2021 |
収益: | $881 705 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。